Cours suspendu

Communiqués Intra-Cellular Therapies, Inc.

Actions

ITCI

US46116X1019

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/04/2025			Varia. 5j.	Varia. 1 janv.
131,87 ^USD	-0,04%		-.--%	-

02/04/25	Johnson & Johnson finalise l'achat de Intra-Cellular Therapies	MT
02/04/25	J&J : acquisition imminente de Intra-Cellular Therapies

Communiqués

25/02/25	INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI	BU
24/02/25	Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results	AQ
21/02/25	Intra-Cellular: Q4 Earnings Snapshot	AQ
21/02/25	Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results	AQ
14/01/25	INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI	BU
13/01/25	J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders	AQ
10/01/25	Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz	AQ
06/01/25	Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference	AQ
11/12/24	Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting	AQ
03/12/24	Intra Cellular Therapies : Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy Form 8 K	PU
03/12/24	Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy	AQ
19/11/24	Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences	AQ
07/11/24	Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress	AQ
05/11/24	Intra Cellular Therapies : Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia Form 8 K	PU
05/11/24	Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia	AQ
30/10/24	INTRA CELLULAR THERAPIES : REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS, PROVIDES CORPORATE UPDATE AND RAISES 2024 CAPLYTA SALES GUIDANCE Form 8 K	PU
30/10/24	Intra-Cellular: Q3 Earnings Snapshot	AQ
30/10/24	Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance	AQ
17/10/24	Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast	AQ
23/09/24	Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress	AQ
28/08/24	Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences	AQ
08/08/24	Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference	AQ
07/08/24	Intra-Cellular: Q2 Earnings Snapshot	AQ
07/08/24	Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer	AQ
07/08/24	Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance	AQ